<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://new.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Tue, 21 Jul 2026 06:57:48 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://new.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Ryder adds free 60-day warranty to used commercial vehicle sales</title>
   <link>http://www.streetinsider.com/Corporate+News/Ryder+adds+free+60-day+warranty+to+used+commercial+vehicle+sales/26791910.html</link>
   <description>&lt;p&gt;Ryder System, Inc. (NYSE: R) has launched the Ryder Vehicle Assurance Program, which includes a free 60-day limited warranty on all Ryder DOT Verified used commercial vehicles, available through the end of the year.&lt;/p&gt;&lt;p&gt;According to a company statement, this is the first time Ryder has offered a free 60-day limited warranty on used commercial vehicles. The warranty covers key powertrain and comfort components. Buyers may also extend coverage through additional warranty plans of 90 days, 12 months, 24 months, or 36 months at additional cost.&lt;/p&gt;&lt;p&gt;DOT Verified vehicles in the program undergo a 140-point inspection and come with a complete maintenance</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Corporate+News/Ryder+adds+free+60-day+warranty+to+used+commercial+vehicle+sales/26791910.html</guid>
   <pubDate>Tue, 21 Jul 2026 06:57:48 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Introduces Free 60‑Day Warranty on Used Commercial Vehicles Through Year‑End</title>
   <link>http://www.streetinsider.com/Press+Releases/Ryder+Introduces+Free+60%E2%80%91Day+Warranty+on+Used+Commercial+Vehicles+Through+Year%E2%80%91End/26791900.html</link>
   <description>
&lt;ul class=&quot;bwlistdisc&quot;&gt;
&lt;li&gt;
New year-end promotional warranty enhances buyer confidence and delivers added protection for Ryder’s used commercial vehicles

&lt;/li&gt;
&lt;li&gt;
Warranty supports business continuity, reduced risk, and road‑ready fleet operations

&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) is expanding its used vehicle sales program with the launch of the Ryder Vehicle Assurance Program, a new offering designed to give buyers greater confidence when purchasing pre-owned commercial vehicles. Through the end of the year, Ryder is introducing a free 60‑day limited warranty on all Ryder DOT Verified vehicles. The promotional offering strengthens Ryder’s position in the commercial vehicle market and provides buyers with</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ryder+Introduces+Free+60%E2%80%91Day+Warranty+on+Used+Commercial+Vehicles+Through+Year%E2%80%91End/26791900.html</guid>
   <pubDate>Tue, 21 Jul 2026 06:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Introduces Free 60‑Day Warranty on Used Commercial Vehicles Through Year‑End</title>
   <link>http://www.streetinsider.com/Press+Releases/Ryder+Introduces+Free+60%E2%80%91Day+Warranty+on+Used+Commercial+Vehicles+Through+Year%E2%80%91End/26791900.html</link>
   <description>
&lt;ul class=&quot;bwlistdisc&quot;&gt;
&lt;li&gt;
New year-end promotional warranty enhances buyer confidence and delivers added protection for Ryder’s used commercial vehicles

&lt;/li&gt;
&lt;li&gt;
Warranty supports business continuity, reduced risk, and road‑ready fleet operations

&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) is expanding its used vehicle sales program with the launch of the Ryder Vehicle Assurance Program, a new offering designed to give buyers greater confidence when purchasing pre-owned commercial vehicles. Through the end of the year, Ryder is introducing a free 60‑day limited warranty on all Ryder DOT Verified vehicles. The promotional offering strengthens Ryder’s position in the commercial vehicle market and provides buyers with</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ryder+Introduces+Free+60%E2%80%91Day+Warranty+on+Used+Commercial+Vehicles+Through+Year%E2%80%91End/26791900.html</guid>
   <pubDate>Tue, 21 Jul 2026 06:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Introduces Free 60‑Day Warranty on Used Commercial Vehicles Through Year‑End</title>
   <link>http://www.streetinsider.com/Business+Wire/Ryder+Introduces+Free+60%E2%80%91Day+Warranty+on+Used+Commercial+Vehicles+Through+Year%E2%80%91End/26791900.html</link>
   <description>
&lt;ul class=&quot;bwlistdisc&quot;&gt;
&lt;li&gt;
New year-end promotional warranty enhances buyer confidence and delivers added protection for Ryder’s used commercial vehicles

&lt;/li&gt;
&lt;li&gt;
Warranty supports business continuity, reduced risk, and road‑ready fleet operations

&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) is expanding its used vehicle sales program with the launch of the Ryder Vehicle Assurance Program, a new offering designed to give buyers greater confidence when purchasing pre-owned commercial vehicles. Through the end of the year, Ryder is introducing a free 60‑day limited warranty on all Ryder DOT Verified vehicles. The promotional offering strengthens Ryder’s position in the commercial vehicle market and provides buyers with</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ryder+Introduces+Free+60%E2%80%91Day+Warranty+on+Used+Commercial+Vehicles+Through+Year%E2%80%91End/26791900.html</guid>
   <pubDate>Tue, 21 Jul 2026 06:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Introduces Free 60‑Day Warranty on Used Commercial Vehicles Through Year‑End</title>
   <link>http://www.streetinsider.com/Business+Wire/Ryder+Introduces+Free+60%E2%80%91Day+Warranty+on+Used+Commercial+Vehicles+Through+Year%E2%80%91End/26791900.html</link>
   <description>
&lt;ul class=&quot;bwlistdisc&quot;&gt;
&lt;li&gt;
New year-end promotional warranty enhances buyer confidence and delivers added protection for Ryder’s used commercial vehicles

&lt;/li&gt;
&lt;li&gt;
Warranty supports business continuity, reduced risk, and road‑ready fleet operations

&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
Ryder System, Inc. (NYSE: R) is expanding its used vehicle sales program with the launch of the Ryder Vehicle Assurance Program, a new offering designed to give buyers greater confidence when purchasing pre-owned commercial vehicles. Through the end of the year, Ryder is introducing a free 60‑day limited warranty on all Ryder DOT Verified vehicles. The promotional offering strengthens Ryder’s position in the commercial vehicle market and provides buyers with</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ryder+Introduces+Free+60%E2%80%91Day+Warranty+on+Used+Commercial+Vehicles+Through+Year%E2%80%91End/26791900.html</guid>
   <pubDate>Tue, 21 Jul 2026 06:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Citizens Starts Ryder Systems (R) at Market Perform</title>
   <link>http://www.streetinsider.com/New+Coverage/Citizens+Starts+Ryder+Systems+%28R%29+at+Market+Perform/26769708.html</link>
   <description>(Updated - July 15, 2026 4:35 AM EDT)

&lt;p&gt;Citizens analyst Jeff Kauffman initiates coverage on Ryder Systems (NYSE: R) with a Market Perform rating.&lt;/p&gt;&lt;p&gt;The analyst comments: &quot;We initiate coverage at Market Perform. Ryder historically trades between 4.0x and 6.0x EV/EBITDA. As a company whose primary business is asset leasing, we generally look to buy the shares under 4.5x EBITDA and sell the shares over 5.5x EBITDA, with an average target valuation across a cycle. Currently, shares are trading above the higher end of the historical range, which we see as fairly valued. This is not to say that a higher average</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/Citizens+Starts+Ryder+Systems+%28R%29+at+Market+Perform/26769708.html</guid>
   <pubDate>Wed, 15 Jul 2026 04:35:21 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Citizens Starts Ryder Systems (R) at Market Perform</title>
   <link>http://www.streetinsider.com/Analyst+Comments/Citizens+Starts+Ryder+Systems+%28R%29+at+Market+Perform/26769708.html</link>
   <description>(Updated - July 15, 2026 4:35 AM EDT)

&lt;p&gt;Citizens analyst Jeff Kauffman initiates coverage on Ryder Systems (NYSE: R) with a Market Perform rating.&lt;/p&gt;&lt;p&gt;The analyst comments: &quot;We initiate coverage at Market Perform. Ryder historically trades between 4.0x and 6.0x EV/EBITDA. As a company whose primary business is asset leasing, we generally look to buy the shares under 4.5x EBITDA and sell the shares over 5.5x EBITDA, with an average target valuation across a cycle. Currently, shares are trading above the higher end of the historical range, which we see as fairly valued. This is not to say that a higher average</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/Citizens+Starts+Ryder+Systems+%28R%29+at+Market+Perform/26769708.html</guid>
   <pubDate>Wed, 15 Jul 2026 04:35:21 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc</title>
   <link>http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</guid>
   <pubDate>Mon, 13 Jul 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19853057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20696623</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc</title>
   <link>http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</guid>
   <pubDate>Mon, 13 Jul 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19853057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20696623</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc</title>
   <link>http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</guid>
   <pubDate>Mon, 13 Jul 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19853057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20696623</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc</title>
   <link>http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</guid>
   <pubDate>Mon, 13 Jul 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19853057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20696623</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc</title>
   <link>http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</guid>
   <pubDate>Mon, 13 Jul 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19853057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20696623</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc</title>
   <link>http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</guid>
   <pubDate>Mon, 13 Jul 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19853057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20696623</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc</title>
   <link>http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</guid>
   <pubDate>Mon, 13 Jul 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19853057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20696623</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc</title>
   <link>http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</guid>
   <pubDate>Mon, 13 Jul 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19853057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20696623</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc</title>
   <link>http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</guid>
   <pubDate>Mon, 13 Jul 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19853057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20696623</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc</title>
   <link>http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</link>
   <description>
&lt;p&gt;    AUSTIN, Texas--(BUSINESS WIRE)--
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

&lt;/p&gt;&lt;p&gt;
OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ollin+Biosciences+Announces+Upcoming+Presentations+of+OLN324+Data+in+Diabetic+Macular+Edema+and+Wet+Age-Related+Macular+Degeneration+at+the+American+Society+of+Retina+Specialists+%28ASRS%29+44th+Annual+Sc/26760024.html</guid>
   <pubDate>Mon, 13 Jul 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">01801</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19853057</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">D</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20696623</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Citi downgrades Ryder Systems to neutral, raises price target</title>
   <link>http://www.streetinsider.com/Downgrades/Citi+downgrades+Ryder+Systems+to+neutral%2C+raises+price+target/26754537.html</link>
   <description>(Updated - July 10, 2026 5:06 AM EDT)

&lt;p&gt;Citi analyst Ben Mohr downgraded Ryder Systems (NYSE: R) from Buy to Neutral, while raising the price target to $280.00 from $276.00.&lt;/p&gt;&lt;p&gt;Mohr cited valuation as the primary reason for the downgrade, noting the decision was based on forward price-to-earnings analysis, peak scenario analysis, and a sum-of-the-parts assessment.&lt;/p&gt;&lt;p&gt;In a note, Mohr said sustained ISM and spot rate strength should continue to benefit all three of Ryder's business segments. He also noted that the company's lease business carries some resilience to interest rate hikes due to interest rate escalators built into its lease agreements and</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Downgrades/Citi+downgrades+Ryder+Systems+to+neutral%2C+raises+price+target/26754537.html</guid>
   <pubDate>Fri, 10 Jul 2026 05:06:46 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder System (R) Raises Quarterly Dividend 11% to $1.01; 1.5% Yield</title>
   <link>http://www.streetinsider.com/Dividends/Ryder+System+%28R%29+Raises+Quarterly+Dividend+11%25+to+%241.01%3B+1.5%25+Yield/26753616.html</link>
   <description>&lt;p&gt;Ryder System (NYSE: R) declared a quarterly dividend of $1.01 per share, or $4.04 annualized. This is an 11% increase from the prior dividend of $0.91.&lt;/p&gt;&lt;p&gt;The dividend will be payable on September 18, 2026, to stockholders of record on August 24, 2026, with an ex-dividend date of August 21, 2026.&lt;/p&gt;&lt;p&gt;The annual yield on the dividend is 1.5 percent.&lt;/p&gt;&lt;p&gt;For a dividend history and other dividend-related data on Ryder System (R) &lt;a href=&quot;http://www.streetinsider.com/dividend_history.php?q=R&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Dividends/Ryder+System+%28R%29+Raises+Quarterly+Dividend+11%25+to+%241.01%3B+1.5%25+Yield/26753616.html</guid>
   <pubDate>Thu, 09 Jul 2026 16:31:41 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder System (R) Raises Quarterly Dividend 11% to $1.01; 1.5% Yield</title>
   <link>http://www.streetinsider.com/Dividend+Hike/Ryder+System+%28R%29+Raises+Quarterly+Dividend+11%25+to+%241.01%3B+1.5%25+Yield/26753616.html</link>
   <description>&lt;p&gt;Ryder System (NYSE: R) declared a quarterly dividend of $1.01 per share, or $4.04 annualized. This is an 11% increase from the prior dividend of $0.91.&lt;/p&gt;&lt;p&gt;The dividend will be payable on September 18, 2026, to stockholders of record on August 24, 2026, with an ex-dividend date of August 21, 2026.&lt;/p&gt;&lt;p&gt;The annual yield on the dividend is 1.5 percent.&lt;/p&gt;&lt;p&gt;For a dividend history and other dividend-related data on Ryder System (R) &lt;a href=&quot;http://www.streetinsider.com/dividend_history.php?q=R&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Dividend+Hike/Ryder+System+%28R%29+Raises+Quarterly+Dividend+11%25+to+%241.01%3B+1.5%25+Yield/26753616.html</guid>
   <pubDate>Thu, 09 Jul 2026 16:31:41 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Increases Quarterly Cash Dividend</title>
   <link>http://www.streetinsider.com/Press+Releases/Ryder+Increases+Quarterly+Cash+Dividend/26753582.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Company Pays Dividend for 200th Consecutive Quarter&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
The Board of Directors of &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.ryder.com%2F&amp;amp;esheet=54567316&amp;amp;newsitemid=20260708369436&amp;amp;lan=en-US&amp;amp;anchor=Ryder+System%2C+Inc.&amp;amp;index=1&amp;amp;md5=c10dedb600b6b7420befc4c828ca5f0e&quot; shape=&quot;rect&quot;&gt;Ryder System, Inc.&lt;/a&gt; (NYSE: R) declared a regular quarterly cash dividend of $1.01 per share of common stock to be paid on September 18, 2026 to shareholders of record on August 24, 2026. This dividend reflects an 11% or $0.10 increase from the $0.91 cash dividend that Ryder had been paying quarterly since July 2025.

&lt;/p&gt;&lt;p&gt;
“Our transformed business model continues to outperform prior cycles and has enabled us to increase our quarterly dividend by 74% since 2021,” says Ryder CEO</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ryder+Increases+Quarterly+Cash+Dividend/26753582.html</guid>
   <pubDate>Thu, 09 Jul 2026 16:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Increases Quarterly Cash Dividend</title>
   <link>http://www.streetinsider.com/Press+Releases/Ryder+Increases+Quarterly+Cash+Dividend/26753582.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Company Pays Dividend for 200th Consecutive Quarter&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
The Board of Directors of &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.ryder.com%2F&amp;amp;esheet=54567316&amp;amp;newsitemid=20260708369436&amp;amp;lan=en-US&amp;amp;anchor=Ryder+System%2C+Inc.&amp;amp;index=1&amp;amp;md5=c10dedb600b6b7420befc4c828ca5f0e&quot; shape=&quot;rect&quot;&gt;Ryder System, Inc.&lt;/a&gt; (NYSE: R) declared a regular quarterly cash dividend of $1.01 per share of common stock to be paid on September 18, 2026 to shareholders of record on August 24, 2026. This dividend reflects an 11% or $0.10 increase from the $0.91 cash dividend that Ryder had been paying quarterly since July 2025.

&lt;/p&gt;&lt;p&gt;
“Our transformed business model continues to outperform prior cycles and has enabled us to increase our quarterly dividend by 74% since 2021,” says Ryder CEO</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Ryder+Increases+Quarterly+Cash+Dividend/26753582.html</guid>
   <pubDate>Thu, 09 Jul 2026 16:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Increases Quarterly Cash Dividend</title>
   <link>http://www.streetinsider.com/Business+Wire/Ryder+Increases+Quarterly+Cash+Dividend/26753582.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Company Pays Dividend for 200th Consecutive Quarter&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
The Board of Directors of &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.ryder.com%2F&amp;amp;esheet=54567316&amp;amp;newsitemid=20260708369436&amp;amp;lan=en-US&amp;amp;anchor=Ryder+System%2C+Inc.&amp;amp;index=1&amp;amp;md5=c10dedb600b6b7420befc4c828ca5f0e&quot; shape=&quot;rect&quot;&gt;Ryder System, Inc.&lt;/a&gt; (NYSE: R) declared a regular quarterly cash dividend of $1.01 per share of common stock to be paid on September 18, 2026 to shareholders of record on August 24, 2026. This dividend reflects an 11% or $0.10 increase from the $0.91 cash dividend that Ryder had been paying quarterly since July 2025.

&lt;/p&gt;&lt;p&gt;
“Our transformed business model continues to outperform prior cycles and has enabled us to increase our quarterly dividend by 74% since 2021,” says Ryder CEO</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ryder+Increases+Quarterly+Cash+Dividend/26753582.html</guid>
   <pubDate>Thu, 09 Jul 2026 16:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Increases Quarterly Cash Dividend</title>
   <link>http://www.streetinsider.com/Business+Wire/Ryder+Increases+Quarterly+Cash+Dividend/26753582.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;Company Pays Dividend for 200th Consecutive Quarter&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    MIAMI--(BUSINESS WIRE)--
The Board of Directors of &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fwww.ryder.com%2F&amp;amp;esheet=54567316&amp;amp;newsitemid=20260708369436&amp;amp;lan=en-US&amp;amp;anchor=Ryder+System%2C+Inc.&amp;amp;index=1&amp;amp;md5=c10dedb600b6b7420befc4c828ca5f0e&quot; shape=&quot;rect&quot;&gt;Ryder System, Inc.&lt;/a&gt; (NYSE: R) declared a regular quarterly cash dividend of $1.01 per share of common stock to be paid on September 18, 2026 to shareholders of record on August 24, 2026. This dividend reflects an 11% or $0.10 increase from the $0.91 cash dividend that Ryder had been paying quarterly since July 2025.

&lt;/p&gt;&lt;p&gt;
“Our transformed business model continues to outperform prior cycles and has enabled us to increase our quarterly dividend by 74% since 2021,” says Ryder CEO</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Ryder+Increases+Quarterly+Cash+Dividend/26753582.html</guid>
   <pubDate>Thu, 09 Jul 2026 16:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.00004304</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
  <item>
   <title>Ryder Systems (R) PT Raised to $280 at Morgan Stanley</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Ryder+Systems+%28R%29+PT+Raised+to+%24280+at+Morgan+Stanley/26731722.html</link>
   <description>Morgan Stanley analyst Christyne McGarvey raised the price target on Ryder Systems (NYSE: R) to $280.00  (from $263.00) while maintaining a Overweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Ryder+Systems+%28R%29+PT+Raised+to+%24280+at+Morgan+Stanley/26731722.html</guid>
   <pubDate>Mon, 06 Jul 2026 04:12:14 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">R</category>
   	  </item>
 </channel>
</rss>
